We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ANDA Reviews Slowed By Missing Compliance Data, FDA Officials Say
ANDA Reviews Slowed By Missing Compliance Data, FDA Officials Say
June 4, 2012
Generic-drug makers are contributing to review delays because, intentionally or not, their ANDAs too often fail to provide a full list of personnel and facilities involved in drug manufacturing and testing, FDA officials say.